It is worth noting that GPX4 can be a latent therapeutic target in some hard-to-treat cancers such as clear-cell carcinomas (CCCs) that have an intrinsic vulnerability to GPX4 inhibition-induced ferroptosis. This evidence concerns the gene GPX4 and clear cell adenocarcinoma.